AdventHealth physician discusses how a new Florida board can help overcome clinical challenges of rare diseases

As part of Healthcare Innovation’s Advancing Digital Healthcare Delivery, a monthly digital health virtual series with innovators who are transforming healthcare, Rajan Wadhawan, M.D., neonatologist and senior executive officer of AdventHealth for Children and AdventHealth for Women, candidly discussed the clinical challenges of rare diseases and how a new board for the state of Florida is working to improve health outcomes for patients living with these diseases.

Healthcare Innovation Advancing Digital Healthcare Delivery with Rajan Wadhawan, M.D.

Watch Healthcare Innovation’s Advancing Digital Healthcare Delivery, a monthly digital health virtual series with innovators who are transforming healthcare, with AdventHealth's Rajan Wadhawan, M.D.

“Rare diseases are usually chronic and involve multiple systems, and almost all of these conditions have a genetic cause, which means they are manifesting in infants,” said Wadhawan. Because of these complexities, they are difficult to diagnose and manage, often causing a delay in care.

“Diagnosing a rare disease can take four to five years and oftentimes it includes an earlier misdiagnosis,” he said.

While rare diseases are classified as those that affect less than 200,000 people in the U.S., there are more than 7,000 different types of rare diseases – and each present with their own nuanced conditions and symptoms. All of these combined impacts an immense number of people: nearly 1 in 10 Americans are estimated to be living with rare diseases.

“The knowledge base for every condition is so vast, it is not possible for an average practicing physician to know everything about every rare disease,” Wadhawan said.

Rajan Wadhawan, M.D. is a neonatologist and senior executive officer of AdventHealth for Children and AdventHealth for Wome
Rajan Wadhawan, M.D. is a neonatologist and senior executive officer of AdventHealth for Children and AdventHealth for Women.

During his four-year term on Florida’s newly established Rare Disease Advisory Council (RDAC), Wadhawan will provide his expertise and personal perspective to encourage potential policy changes to make it easier for physicians and patients. This could include developing an online repository of searchable information to improve the diagnosis process and a consortium within the state or region to conduct rare disease research.

“Just like anything in life, there is so much that needs to be done that it can be overwhelming and daunting, but you have to start somewhere,” Wadhawan concludes. “We cannot be frozen by or paralyzed by the enormity of a challenge. If we first examine the areas where we can have the most impact, within the areas where we are experts, we can take it from there.”

As one of 20 representatives on Florida’s RDAC, Wadhawan and his colleagues are working to improve health outcomes for those with a rare disease and making recommendations to state leaders on critical issues, including the need for increased awareness, diagnostic tools and access to affordable treatments and cures.

Recent News

12 items. To interact with these items, press Control-Option-Shift-Right Arrow. These items are in a slider. To advance slider forward, press Shift-Command-Right Arrow. To advance slider backward, press Shift-Command-Left Arrow.
News
AdventHealth Celebration Successfully Performs First Robotics-assisted Cochlear Implant Procedure in Florida with the iotaSOFT® Insertion System.

In January 2024, AdventHealth Celebration neurotologist Michael Seidman, MD, FACS, became the first in Florida and the Southeast to complete a robotics-assisted cochlear implant procedure using the...

Read Article about "AdventHealth Celebration Successfully Performs First Robotics-assisted Cochlear Implant Procedure in Florida with the iotaSOFT® Insertion System."
News
New England Journal of Medicine highlights Guru Sonpavde, MD’s work in new immunotherapy-chemotherapy combination improving survival for patients with advanced urothelial carcinoma

The CheckMate 901 Phase III clinical trial results, recently published in the New England Journal of Medicine, found that combining the programmed death 1 (PD1) inhibitor immunotherapy nivolumab with...

Read Article about "New England Journal of Medicine highlights Guru Sonpavde, MD’s work in new immunotherapy-chemotherapy combination improving survival for patients with advanced urothelial carcinoma"
View More Articles